Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Dose Limiting Toxicity
at the end of the first cycle of the study
Yes
Bristol-Myers Squibb
Study Director
Bristol Myers
Japan: Pharmaceuticals and Medical Devices Agency
CA182-012
NCT00390936
October 2007
March 2010
Name | Location |
---|